Trials / Conditions / TP53 Gene Mutation

TP53 Gene Mutation

10 registered clinical trials studyying TP53 Gene Mutation — 6 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AML NCT07511062	Northside Hospital, Inc.	Phase 1
Not Yet Recruiting	A Clinical Trial of Firsekibart, Tislelizumab, and Lenvatinib in Patients With Unresectable, TP53-Mutated Hepa NCT07535840	Tongji Hospital	N/A
Recruiting	Germline Genetic Testing of the TP53 Gene NCT07419893	European Institute of Oncology	—
Recruiting	Oral-ATO for TP53-mutated Myeloid Malignancies NCT06778187	The University of Hong Kong	Phase 2
Not Yet Recruiting	Translational Study of MSS, TP53 Mutation and Chromosome Instability Relationship in Endometrial Carcinoma NCT06521684	Peking Union Medical College Hospital	—
Completed	Patogenic Mutation in 5 Genes NCT04976439	Dr Cipto Mangunkusumo General Hospital	—
Terminated	Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malig NCT03272633	Rutgers, The State University of New Jersey	EARLY_Phase 1
Recruiting	Li-Fraumeni & TP53 (LiFT UP): Understanding and Progress NCT04541654	Dana-Farber Cancer Institute	—
Terminated	The p53 Colorectal Cancer Trial NCT03149679	Haukeland University Hospital	Phase 2
Active Not Recruiting	Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy NCT02432963	City of Hope Medical Center	Phase 1